Press Releases

    Print Page  Close Window
BioMed Realty Trust Prices Public Offering of Common Stock

SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the pricing of its public offering of 9,075,000 shares of its common stock at $28.65 per share, reflecting an increase from its previously announced offering size of 8,000,000 shares. The offering is expected to close on May 16, 2006. Gross proceeds from the offering will be approximately $260 million. All of the shares are being sold by the company.

Raymond James & Associates, Inc. is the sole book-running manager for the offering, with Citigroup Global Markets Inc. acting as co-lead manager and KeyBanc Capital Markets, a division of McDonald Investments Inc., Wachovia Capital Markets, LLC, Friedman Billings Ramsey & Co., Inc., RBC Capital Markets, Stifel Nicolaus & Company, Incorporated and BB&T Capital Markets, a division of Scott & Stringfellow, Inc., acting as co-managers. BioMed also granted the underwriters a 30-day option to purchase up to an additional 1,361,250 shares to cover over-allotments, if any.

BioMed expects to use the net proceeds of this offering to fund a portion of the purchase price of its previously announced acquisition of Human Genome Sciences' large-scale manufacturing and headquarters office and laboratory facilities located in Rockville, Maryland, for which BioMed has signed a definitive purchase and sale agreement.

The registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of BioMed's common stock, nor shall there be any sale of such common stock in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state. The offering of BioMed's common stock will be made only by means of a prospectus and a related prospectus supplement, copies of which, when available, may be obtained by contacting Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, FL 33716.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(TM). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry, and its properties and primary acquisition targets are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. BioMed's real estate portfolio consists of 43 properties, representing 64 buildings with approximately 4.8 million rentable square feet in each of the major life science markets in the United States. Additional information is available at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, which could affect the actual results and timing of the offering, include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions successfully, including the acquisition of the Human Genome Sciences properties; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: BioMed Realty Trust, Inc.

CONTACT: Kent Griffin, Chief Financial Officer of BioMed Realty Trust, Inc., +1-858-485-9840
Web site:

05/10/2006 22:34 EDT